© 2024 Connecticut Public

FCC Public Inspection Files:
WEDH · WEDN · WEDW · WEDY · WNPR
WPKT · WRLI-FM · WEDW-FM · Public Files Contact
ATSC 3.0 FAQ
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations

FDA Gives A Nod To "Paradigm Shifting" Cancer Treatment

Wikimedia Commons
A healthy human T-Cell imaged with a scanning electron micrograph.

A key committee for the U.S. Food and Drug Administration issued a first-of-its-kind recommendation this week, unanimously signing off on an experimental cancer treatment. Research for the treatment was funded, in part, by a Connecticut nonprofit.

The therapy is called “CAR-T.”

It samples a patient’s immune cells, called T Cells, engineering them and infusing them back into the body.

“You’re basically educating the T Cells to target a feature of the cancer cells,” said Steven Gore, a doctor at the Yale Cancer Center.

Right now, Gore said the treatment is applicable to only a few patients who have failed existing cancer therapies. But he thinks the FDA is friendly to the idea, and that the technology will be explored for other cancers.

“This is, potentially, paradigm shifting,” said John Walter, President and Chief Executive for Alliance for Cancer Gene Therapy, a nonprofit based in Stamford.

The “CAR-T” technique uses technology from Dr. Carl June at the University of Pennsylvania.

In 2004 and 2008, June received two grants from Alliance for Cancer Gene Therapy, which he put towards his research.

“These things, with enough survival data, could become frontline treatments,” Walter said. “Which would mean for these patients that they no more have to submit themselves to chemotherapy -- potentially bone marrow treatment.”

Walter said if the treatments prove successful long-term, it will validate his organization’s long-standing hypothesis -- that if cancer starts in the cells and the genes, it might be cured there, too. 

Patrick Skahill is a reporter and digital editor at Connecticut Public. Prior to becoming a reporter, he was the founding producer of Connecticut Public Radio's The Colin McEnroe Show, which began in 2009. Patrick's reporting has appeared on NPR's Morning Edition, Here & Now, and All Things Considered. He has also reported for the Marketplace Morning Report. He can be reached at pskahill@ctpublic.org.

Stand up for civility

This news story is funded in large part by Connecticut Public’s Members — listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a better—and more civil—Connecticut to live, work, and play.

Related Content